Skip to content

Empagliflozin Safe in Acute HF, Improves Clinical Benefit Over Time

  • by

Patients with acute heart failure were safely started on empagliflozin a median of 3 days after hospitalization and were 36% more likely to “experience a clinical benefit” over the next 90 days compared with patients taking a placebo, the EMPULSE trial highlights.

Hello and welcome to medical dialogues journal club your daily dose of health and medical news i am dr nandita mohan and i am going to discuss about the impulse trial which aimed to find out whether starting a to take a new medicine called empogliflozin soon after being treated in the hospital helps people recover with acute heart failure empirglyflusin belongs

To a class of medicines known as the sglt2 inhibitors it is used to treat most commonly type 2 diabetes the benefits of the sgl2 inhibitors for patients with chronic heart failure have been well established in larger randomized trials previously but many heart failure specialists most notably the leading clinical trials have advocated for sglt2 inhibitors to be

Started in the hospital as soon as the patients are stable among clinicians more widely however there is very reluctance in starting a chronic heart failure drug in a more acute heart failure setting the impulse investigators randomized approximately 530 patients into two groups one group took the one empagliflozin tablet a day the other group took one placebo

Tablet a day the administration was done as soon as the patients were stabilized in the hospital then followed them up for 90 days for the primary composite end endpoint of time of death frequency of heart failure events or even the time to first heart failure event the trial results were presented at the aha conference which stated that the benefits of m fugly

Flows in in this very acute sitting setting included better survival fewer hospitalizations and greater improvements in the quality of life the patients that were treated with this particular drug were 36 percent more likely to experience a clinical benefit in the first 90 days patients experienced improvements regardless of the type of heart failure or whether

They had diabetes or not and importantly in these patients there was no safety concerns with the use of mphagliflozin the drug has now demonstrated efficacy really across a continuum of ejection fraction in the stable ambulatory outpatient population and now in those admitted with acute heart failure these trial results will impact the practice of clinicians

Worldwide and that’s because acute heart failure is the number one cause of hospitalization in individuals over the age of 65 in many regions of the world this is a widely available drug so impulse has massive implications in terms of use we have today with us dr prem agarwal a senior cardiologist at sanjeevan hospital sir if you could share your thoughts on

How amphagliflozin can help in acute heart failure will provide us with insights thank you with this sample style we are reaching to new developments in the medical science and this emphasis stopping to keep surprising us with new results uh after having uh used it in preserved rejection fraction now the impulse trial is showing good results even acute heart

Failure in fact the hypothesis was used that since we are using it in the reduced section fraction then using it in early hospitalization stage that when the patient is with their heart failure is admitted in the hospital in acute heart failure stays at that time we will start a amphoglobin early then whether it will be useful or not and this particular thing

Has been tested in impulse trial and it has been found out that the benefit of amphaglophysion has been found in even acute settings also including better survival better and greater improvement quality of life and all this makes the primary endpoints in everywhere it has found improvement in by giving amphoglovision early and this uh inhibitor this while the

Benefits of this as cl2 inhibitors have been found to be very useful in chronic heart failure but first time as a leading trial and landmark trial it has been used in an impulse trial where they have used it in acute heart failure i think that um this trial will have a long-term impact on the clinical uses of epheglophysism that when we are you trying to use it

For reducing heart failure giving better calculate clinical benefits better quality of life reduce hospitalization it will be if it is started early an impulse trial has a unique that it is one third of the patients who always come to us has been randomized by the new onset uh good heart failure and this is a new onset heart failure and if we start emphasising

It finds benefit so i think that is a good development and this global vision a good medicines which are used in different situations and they have to be uniformly found to be useful thank you never miss a medical update from medical dialogues like subscribe and press the bell icon

Transcribed from video
Empagliflozin Safe in Acute HF, Improves ‘Clinical Benefit’ Over Time By Medical Dialogues